https://www.live-feeds.com/feed/moderna-ceo-tells-what-the-market-got-wrong-about-its-cancer-vaccineContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/moderna-ceo-tells-what-the-market-got-wrong-about-its-cancer-vaccinehttps://www.live-feeds.com/feed/moderna-ceo-tells-what-the-market-got-wrong-about-its-cancer-vaccine#u163663Fri, 30 Oct 2026 11:15:33 +0000Moderna shares remained steady following a data leak crash and subsequent study updates regarding its personalized cancer vaccine developed with Merck. Moderna CEO Stéphane Bancel addressed market misconceptions about the treatment, pointing to potential applications beyond melanoma. Late-stage trial data showed promising results, including a lower death risk and positive indicators for kidney cancer treatment. While the market initially slid despite the trial successes, leadership maintains that the therapeutic platform holds broad promise across multiple oncology indications.Why it mattersTh